

Expanding therapeutic options for schizophrenia: Considering patient preferences when developing novel treatments

Date: Monday 23rd September 2024

Time: 08:30–10:00 (GMT+1)

Venue: Auditorium, Allianz MiCo – Milano Convention Centre, Milano, Italy

Industry session financially supported by Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S during the 37th ECNP Congress.

Agenda

08:30–08:35	Chair's introduction	Charlotte Emborg Mafi, Denmark
08:35–08:55	Improving medication adherence in the maintenance treatment of schizophrenia: What can we learn from preference studies?	Sofia Pappa, UK
08:55–09:15	Developing novel treatment formulations for schizophrenia: How can we minimise risk to patients when designing clinical trials?	Ric Procyshyn, Canada
09:15–09:35	Interpreting data for novel treatment formulations for schizophrenia: How do pharmacokinetic data translate to clinical efficacy?	Leslie Citrome, USA
09:35–09:55	Discussion/Q&A, moderated by Chair	All faculty
09:55–10:00	Summary and close	Charlotte Emborg Mafi, Denmark

This meeting has been organised and funded by Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S. Information on Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S products will be presented at this meeting, which is intended for healthcare professionals only.

